Divalproex Sodium Tablet, Delayed Release
Product Images NDC 70518-2357

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 70518-2357). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium 500mg 70518 2357 01

Divalproex Sodium 500 mg delayed-release tablets in a quantity of 100, repackaged by RemedyRepack Inc. The label includes NDC 70518-2357-01 and manufacturing information from Rising Pharma, Inc. The label advises directions to see the package insert and storage conditions at 20-25°C with permitted excursions.*

FDA Label Image

Divalproex Sodium 500mg 70518 2357 02

The packaging label for Divalproex Sodium delayed-release tablet, 500 mg, quantity 1, repackaged by RemedyRepack Inc. The label includes the NDC number 70518-2357-02, storage instructions (20-25°C with excursions allowed), and manufacturer info (Rising Pharma, Inc., Allendale, NJ). Directions for use refer to the package insert.*

FDA Label Image

Divalproex Sodium 500mg 70518 2357 03

Divalproex Sodium 500 mg delayed-release tablets packaging label showing quantity of 100 tablets. The label includes drug name, dosage form, strength, manufacturer (Rising Pharma, Inc., Allendale, NJ), repackager (RemedyRepack Inc., Indiana, PA), and storage instructions. Marked RX only with NDC 70518-2357-03.*

FDA Label Image

Divalproex Sodium 500mg 70518 2357 04

Divalproex Sodium 500 mg delayed-release tablet label showing a single tablet quantity. The label includes the proprietary name, dosage strength, form, and repackager RemedyRepack Inc. It also lists manufacturer Rising Pharma, Inc., directions to see package insert, storage instructions, and a QR code.*

FDA Label Image

Remedy_label (Remedy Label)

Divalproex Sodium 500 mg delayed-release oral tablets label showing quantity of 30 tablets. The label includes the NDC number 70518-2357-00, manufacturer Rising Pharma, Inc., Allendale, NJ, and repackager RemedyRepack Inc., Indiana, PA. Directions reference the package insert for use details.*

FDA Label Image

Figure 1 (Divalproex Fig1)

A bar chart comparing the percentage outcomes between placebo (PBO) and divalproex sodium delayed-release tablets (DVPX) across two studies. Study 1 (YMRS) shows 26% for placebo and 60% for DVPX, while Study 2 (MRS) shows 29% for placebo and 58% for DVPX. Statistical significance is indicated with p < 0.05.*

FDA Label Image

Figure 2 (Divalproex Fig2)

A Kaplan-Meier curve chart comparing the percent reduction in CPS rate for Divalproex Sodium Delayed-Release Tablets versus placebo. The y-axis shows percent reduction ranging from -100% to 100%, indicating worsening to improvement, while the x-axis represents the percentage of patients from 0% to 100%. The solid line represents Divalproex Sodium, showing greater improvement compared to the dashed line for placebo.*

FDA Label Image

Figure 3 (Divalproex Fig3)

A line graph comparing the percentage reduction in Clinical Feature Score (CFS) rate between high and low doses of a treatment. The x-axis represents the percentage of patients, and the y-axis shows the percentage reduction in CFS rate, with labels indicating improvement or worsening. The graph includes two lines: a solid line for high dose and a dashed line for low dose, illustrating patient response distributions.*

FDA Label Image

Figure 4 (Divalproex Fig4)

A bar graph titled 'Figure 4 Mean 4-week Migraine Rates' comparing migraine rates for placebo versus divalproex sodium delayed-release tablets across two studies. Study 1 shows higher migraine rates for placebo than for Divalproex Sodium, and Study 2 shows similar trends with migraine rates lower for Divalproex Sodium doses of 500 or 1,000 mg/day compared to placebo.*

FDA Label Image

Chemical Structure (Divalproex Str)

Chemical structure diagram of divalproex sodium, showing the arrangement of carbon, hydrogen, oxygen, and sodium atoms in its molecular form as a repeating polymer unit.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.